Great Point Partners LLC Sells 2,147,473 Shares of UroGen Pharma Ltd. (NASDAQ:URGN)

Great Point Partners LLC lowered its stake in UroGen Pharma Ltd. (NASDAQ:URGN - Free Report) by 73.9% in the 3rd quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor owned 758,786 shares of the company's stock after selling 2,147,473 shares during the period. UroGen Pharma makes up approximately 2.8% of Great Point Partners LLC's investment portfolio, making the stock its 16th biggest position. Great Point Partners LLC owned 3.24% of UroGen Pharma worth $9,637,000 as of its most recent SEC filing.

A number of other hedge funds and other institutional investors have also added to or reduced their stakes in URGN. Point72 Asset Management L.P. raised its holdings in UroGen Pharma by 120.3% during the 2nd quarter. Point72 Asset Management L.P. now owns 2,449,277 shares of the company's stock valued at $41,099,000 after buying an additional 1,337,257 shares during the period. Millennium Management LLC lifted its stake in UroGen Pharma by 2,672.0% in the second quarter. Millennium Management LLC now owns 1,160,899 shares of the company's stock worth $19,480,000 after purchasing an additional 1,119,019 shares during the last quarter. Cowen AND Company LLC boosted its position in shares of UroGen Pharma by 29.1% during the second quarter. Cowen AND Company LLC now owns 2,099,482 shares of the company's stock valued at $35,229,000 after buying an additional 472,893 shares during the period. Price T Rowe Associates Inc. MD purchased a new position in shares of UroGen Pharma during the first quarter valued at approximately $4,008,000. Finally, Rice Hall James & Associates LLC grew its stake in shares of UroGen Pharma by 273.6% during the third quarter. Rice Hall James & Associates LLC now owns 271,897 shares of the company's stock valued at $3,453,000 after buying an additional 199,110 shares during the last quarter. 91.29% of the stock is currently owned by hedge funds and other institutional investors.

Analysts Set New Price Targets

A number of analysts have weighed in on the company. Oppenheimer reiterated an "outperform" rating and issued a $40.00 target price on shares of UroGen Pharma in a research note on Wednesday, October 16th. HC Wainwright reaffirmed a "buy" rating and issued a $60.00 price target on shares of UroGen Pharma in a research note on Tuesday, October 15th. Guggenheim initiated coverage on shares of UroGen Pharma in a research report on Thursday, August 22nd. They issued a "buy" rating and a $40.00 price objective for the company. Finally, EF Hutton Acquisition Co. I raised shares of UroGen Pharma to a "strong-buy" rating in a research report on Monday, October 14th. Four analysts have rated the stock with a buy rating and one has given a strong buy rating to the stock. According to MarketBeat.com, UroGen Pharma presently has a consensus rating of "Buy" and a consensus target price of $48.38.

UroGen Pharma Stock Performance

Shares of NASDAQ URGN opened at $12.48 on Wednesday. The company has a quick ratio of 8.77, a current ratio of 9.00 and a debt-to-equity ratio of 4.77. UroGen Pharma Ltd. has a 12-month low of $10.60 and a 12-month high of $20.70. The stock's fifty day simple moving average is $12.38 and its two-hundred day simple moving average is $14.01.

UroGen Pharma (NASDAQ:URGN - Get Free Report) last announced its earnings results on Wednesday, November 6th. The company reported ($0.55) EPS for the quarter, topping analysts' consensus estimates of ($0.84) by $0.29. The firm had revenue of $25.20 million during the quarter, compared to the consensus estimate of $24.22 million. During the same quarter in the prior year, the firm posted ($0.68) earnings per share. Equities analysts expect that UroGen Pharma Ltd. will post -3.1 EPS for the current year.

UroGen Pharma Profile

UroGen Pharma Ltd., a biotechnology company, engages in the development and commercialization of solutions for urothelial and specialty cancers. It offers RTGel, a novel proprietary polymeric biocompatible, reverse thermal gelation hydrogel technology to improve therapeutic profiles of existing drugs; and Jelmyto for pyelocalyceal solution.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.